Scynexis (SCYX) Depreciation & Amortization (CF) (2013 - 2023)
Scynexis (SCYX) posted Depreciation & Amortization (CF) of $129000.0 for Q4 2023, down 12.24% on a QoQ basis from $147000.0 in Q3 2023, and down 16.77% year-over-year from $155000.0 in Q4 2022.
Scynexis (SCYX) Depreciation & Amortization (CF) (2013 - 2023) Analysis & Trends
Scynexis' Depreciation & Amortization (CF) history runs 11 years deep, the most recent figure standing at $129000.0 for Q4 2023.
- Quarterly Depreciation & Amortization (CF) fell 16.77% year-over-year to $129000.0 in Q4 2023, while the trailing twelve-month figure through Sep 2024 was $129000.0 (down 78.71% YoY) and the FY2023 annual result came in at $580000.0, down 4.29% from the prior year.
- Depreciation & Amortization (CF) was $129000.0 for Q4 2023 at Scynexis, down from $147000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $246000.0 in Q4 2021 and bottomed at $26000.0 in Q3 2019.
- A 5-year average of $93800.0 and a median of $88000.0 in 2020 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2019 — Depreciation & Amortization (CF) soared 2900.0% — and 2022, when it plunged 36.99%.
- Scynexis' Depreciation & Amortization (CF) stood at $26000.0 in 2019, then surged by 353.85% to $118000.0 in 2020, then jumped by 108.47% to $246000.0 in 2021, then tumbled by 36.99% to $155000.0 in 2022, then declined by 16.77% to $129000.0 in 2023.
- Business Quant data shows SCYX's Depreciation & Amortization (CF) at $129000.0 in Q4 2023, $147000.0 in Q3 2023, and $153000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Scynexis | 21.55 Mn | -15.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 129,000.00 |
| Dec 31, 2023 | 129,000.00 |
| Sep 30, 2023 | 147,000.00 |
| Sep 30, 2023 | 147,000.00 |
| Jun 30, 2023 | 153,000.00 |
| Jun 30, 2023 | 153,000.00 |
| Mar 31, 2023 | 151,000.00 |
| Mar 31, 2023 | 151,000.00 |
| Dec 31, 2022 | 155,000.00 |
| Dec 31, 2022 | 155,000.00 |
| Sep 30, 2022 | 150,000.00 |
| Sep 30, 2022 | 150,000.00 |
| Jun 30, 2022 | 146,000.00 |
| Jun 30, 2022 | 146,000.00 |
| Mar 31, 2022 | 155,000.00 |
| Mar 31, 2022 | 155,000.00 |
| Dec 31, 2021 | 246,000.00 |
| Dec 31, 2021 | 246,000.00 |
| Sep 30, 2021 | 48,000.00 |
| Sep 30, 2021 | 48,000.00 |